Companies › Pfizer · Global Markets & Policy
Pfizer Inc.
- NYSE: PFE
US drugmaker selling medicines and vaccines across cancer, internal medicine and infectious diseases.
Next earnings report: Nov 3, 2026. Pfizer quarterly results and earnings history →
Insider trades (Form 4)
Last 120 days: open-market sales $83K, purchases $3.0M. All Pfizer insider transactions →
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Albert Bourla Chairman & CEO, Director | Open-market purchase | 38,000 | $26.34 | $1.0M | Form 4 ↗ |
| Aug 5, 2026 | Jennifer B. Damico SVP & Controller | Open-market sale | 3,278 | $25.40 | $83K | Form 4 ↗ |
| Aug 5, 2026 | Ronald E Blaylock Director | Open-market purchase | 39,231 | $25.46 | $999K | Form 4 ↗ |
| Aug 5, 2026 | Mortimer J Buckley Director | Open-market purchase | 37,632 | $25.52 | $960K | Form 4 ↗ |
Key financials
| Metric | FY to Dec 2022 | FY to Dec 2023 | FY to Dec 2024 | FY to Dec 2025 |
|---|---|---|---|---|
| Revenue | $101.2B | $59.6B | $63.6B | $62.6B |
| Net income | $31.4B | $2.1B | $8.0B | $7.8B |
| Diluted EPS | $5.47 | $0.37 | $1.41 | $1.36 |
Fiscal years, from annual reports (10-K / 20-F). Source: SEC EDGAR (XBRL company facts), retrieved 2026-10-14. Verify figures against the original filings.
Recent filings
- 2026-08-04 · 10-Q
- 2026-08-04 · 8-K — Results of operations
- 2026-06-18 · 8-K — Regulation FD disclosure
- 2026-06-18 · 8-K — Director or officer change
- 2026-05-05 · 10-Q
- 2026-05-05 · 8-K — Results of operations
- 2026-04-27 · 8-K — Shareholder vote results
- 2026-03-12 · DEF 14A
Source: SEC EDGAR, retrieved 2026-10-14. Filing types explained: 8-K, 10-Q, 10-K, 20-F / 6-K.
Not investment advice. This page lists official filings and our reports for reference. SignalStack does not rate securities or recommend buying or selling anything.